SAN DIEGO, May 9, 2024 /PRNewswire/ --Kate Therapeutics Inc.(“KateTx”), a next-generation gene therapy company, will present detailed preclinical efficacy and safety results on its pipeline and platform at the American Society of Gene and Cell ...
Degraders of TEAD Transcription Factors Based on Interface 3 Binders, American Association for Cancer Research (AACR) Annual Meeting 2024, San Diego, California. Sunday, 7 April, 2024. Related press releases Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the...
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, provided...
a small molecule CCR2 antagonist developed by Centrexion Therapeutics, on knee osteoarthritis pain in osteoarthritis patients aged 40 to 90. The study, estimated to be completed in May 2024, will employ a crossover design; subjects will be randomly assigned to receive CNTX-6970 or a placebo for...
With the sustained commitment of all of partners – donors, scientists, academics and the pharmaceutical industry – the next decade will be a very exciting time to be in clinical development of new therapeutics for malaria.Abbreviations ACPR28: Adequate clinical and parasitological response at day ...
Tedizolid phosphate (9a)91–93 (torezolid phosphate, TR-701, DA-7218) is an oxazolidinone being developed by Trius Therapeutics (San Diego, CA, USA) that has completed a phase-III trial for the treatment of Gram-positive ABSSSi (NCT01170221).94 Discovered by Dong-A Pharmaceutical (Seoul, ...
, Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will b...
Loomba also presented the latest results from a Phase IIa trial of VK2809, a thyroid receptor beta agonist from Viking Therapeutics. This study included 47 people with NAFLD and elevated LDL and triglyceride levels. They were randomly assigned to receive one of three oral regimens of VK2809 (5...
Development status, indication (Developer) CDI MAA in September 2010 and NDA November 2010 (Optimer) Phase-III cSSSi (Paratek/Novartis) Phase-III ABSSSI (Trius Therapeutics) Phase-III ABSSSi (The Medicines Company) Phase-III ABSSSi (Durata Therapeutics) CAP NDA submitted October 2008 but rejected ...
SAN DIEGO,Jan. 05, 2023(GLOBE NEWSWIRE) --Fate Therapeutics, Inc.(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune ...